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Abstract
Background: Diminished expression or activity of prostate apoptosis response protein 4 (Par-4) has been 
demonstrated in a number of cancers, although reports on Par-4 expression during colon cancer progression are 
lacking. An understanding of the molecular events in conjunction with the genetic networks affected by Par-4 is 
warranted.
Results: Colon cancer specimens derived from patients have significantly diminished expression of Par-4 mRNA 
relative to paired normal colon. Hence, the functional consequences of reintroducing Par-4 into HT29 colon cancer 
cells were assessed. Overexpression augmented the interaction of Par-4 with NFκB in the cytosol but not nucleus, and 
facilitated apoptosis in the presence of 5-fluorouracil (5-FU). Analogous findings were obtained when AKT1 pro-
survival signaling was inhibited. Transcriptome profiling identified ~700 genes differentially regulated by Par-4 
overexpression in HT29 cells. Nearly all Par-4-regulated genes were shown by promoter analysis to contain cis-binding 
sequences for NFκB, and meta-analysis of patient expression data revealed that one-third of these genes exist as a 
recurrent co-regulated network in colon cancer specimens. Sets of genes involved in programmed cell death, cell cycle 
regulation and interestingly the microRNA pathway were found overrepresented in the network. Noteworthy, Par-4 
overexpression decreased NFκB occupancy at the promoter of one particular network gene DROSHA, encoding a 
microRNA processing enzyme. The resulting down-regulation of DROSHA was associated with expression changes in a 
cohort of microRNAs. Many of these microRNAs are predicted to target mRNAs encoding proteins with apoptosis-
related functions. Western and functional analyses were employed to validate several predictions. For instance, miR-
34a up-regulation corresponded with a down-regulation of BCL2 protein. Treating Par-4-overexpressing HT29 cells 
with a miR-34a antagomir functionally reversed both BCL2 down-regulation and apoptosis by 5-FU. Conversely, 
bypassing Par-4 overexpression by direct knockdown of DROSHA expression in native HT29 cells increased miR-34a 
expression and 5-FU sensitivity.
Conclusion: Our findings suggest that the initiation of apoptotic sensitivity in colon cancer cells can be mediated by 
Par-4 binding to NFκB in the cytoplasm with consequential changes in the expression of microRNA pathway 
components.
Background
An estimated 400 000 people die of colorectal cancer
yearly worldwide [1]. In the US, it is the second leading
cause of cancer-related deaths (American Cancer Society,
Cancer Facts and Figures 2008). Colon cancer-related
mortality often results from metastases, frequently to the
liver, that are present at the time of diagnosis. Treatment
for metastatic colorectal cancer usually involves a combi-
nation of surgery with adjuvant chemotherapy and/or
radiation. 5-fluorouracil (5-FU), or a related fluoropyrim-
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idine, has been used as a component of the therapeutic
regimen for colon cancer patients for four decades [2-4].
However, despite a combination of 5-FU with other che-
motherapeutic agents, the clinical response rate for
patients with liver metastases remains 20-39% [5], indi-
cating a need for a more effective regimen.
Targets of chemotherapy include oncogene products
such as RAS and SRC, growth factor receptors, and DNA
replication machinery. Therapeutic agents consist of
nonspecific growth inhibitors such as 5-FU and metho-
trexate which cause death to any dividing cell, as well as
specific targeting drugs. The number of specific targets
continues to expand and includes tyrosine kinases for sig-
nal transduction, vascular endothelial growth factor for
angiogenesis, and growth factors [6-9]. However, the tar-
geting of tumor suppressor genes for therapy poses a dif-
ferent problem. The activity of a tumor suppressor must
be induced by replacing or enhancing a missing or inac-
tive protein, respectively, rather than repressing an active
protein. The tumor suppressor Par-4 is one such protein
being studied as a potential molecular target of cancer
therapy [10]. Notwithstanding the potential of Par-4 to be
a suitable molecular target, an understanding of Par-4
function in different cancers is warranted. Par-4 is widely
expressed in cells, contains a leucine zipper domain
through which it interacts with other proteins, and was
first isolated from prostate cancer cells undergoing apop-
tosis [11-13].
The down-regulation of Par-4 has been proposed to be
a critical event in tumorigenesis [14]. Par-4 is down-regu-
lated in a number of cancers; namely, endometrial [15],
renal cell carcinoma [16], pancreatic [17], and lung can-
cer [18]. Furthermore, Par-4 has been shown to be inacti-
v a t e d  b y  A K T 1  i n  p r o s t a t e  c a n c e r  c e l l s ,  a n d  a  P a r - 4 /
AKT1 interaction is widely found in prostate cancer, lung
cancer, cervical cancer, as well as in benign prostatic
hyperplasia and normal human embryonic lung fibro-
blasts [19]. The phosphorylation of Par-4 by AKT1
enables the scaffolding protein 14-3-3 to bind Par-4, caus-
ing retention in the cytoplasm [19,20].
Overexpressing Par-4 can increase susceptibility of
cancer cells to apoptotic agents such as doxorubicin,
tumor necrosis factor alpha (TNF-α), and tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL)
[12,16,21]. While inhibition of Par-4 was shown to reduce
sensitivity to exogenous apoptotic stimuli [13,22], Par-4 is
essential but not sufficient on its own to sensitize cells to
apoptosis [19,23]. Par-4 activity leads to apoptosis via
both extrinsic and intrinsic pathways [24-26]. Intrinsic
pathways include inhibiting transcriptional regulation by
NFκB [25,27,28]. It has been shown that Par-4 inhibits
NFκB through multiple mechanisms, such as: (i) Par-4
inhibits RAS- and RAF-induced transcriptional activa-
tion of NFκB, without affecting IκB degradation or NFκB
nuclear translocation [29]; or (ii) Par-4 binds and seques-
ters ζPKC [30] (ζPKC phosphorylates IκB kinase which in
turn phosphorylates IκB leading to disruption of the
NFκB/IκB complex and nuclear translocation of NFκB),
enhancing apoptosis initiated by TNFα [27].
Although it has been reported that Par-4 expression
can be regulated by nonsteroidal anti-inflammatory
drugs in colon cancer cells [31], little has been published
on the role of Par-4 in colon cancer, nor has there been an
investigation of Par-4 expression as a function of colon
cancer progression. We have recently shown that the
human colon cancer cell line HT29 becomes sensitized to
apoptosis in response to in vivo delivery of Par-4 and 5-
FU treatment in an animal model [32]. This study was
undertaken to examine the mechanism by which Par-4
induces apoptosis in colon cancer cells. We provide evi-
dence for an alternative intrinsic pathway/network
involving Par-4 partnering with NFκB in the cytoplasm,
disruption of DROSHA gene transcription, dysregulation
of microRNAs leading to up-regulation of pro-apoptotic
and down-regulation of pro-survival targets, and apop-
totic sensitization of colon cancer cells to 5-FU.
Results
Par-4 expression in colon cancer specimens and cell lines
Quantitative RT-PCR analysis revealed a significant ~3-
fold down-regulation of PAR-4 mRNA (P < 0.05, paired t-
test; n = 11 paired samples) in colon cancer patient sam-
ples compared with paired normal colon (Additional file
1). To examine the downstream effects of overexpressing
Par-4 into colon cancer cells, HT29 cells were transfected
with an expression vector containing the PAR-4 cDNA.
Western blot confirmed Par-4 overexpression in the
HT29 transfectants (Figure 1A), resulting in increased
sensitivity to 5-FU-mediated apoptosis as defined by cas-
pase activity (Figure 1B). In contrast, empty vector-trans-
fected HT29 cells were resistant to 5-FU treatment
(Figure 1B).
Par-4 binds to NFκB upon inhibition of AKT1
Apoptotic activity of Par-4 is reduced when bound and
phosphorylated by AKT1 in prostate cancer cell lines
[15,19,33]. Potentially, if AKT1 is inhibited in native (i.e. -
no heterologous Par-4 expression) HT29 and SW480
colon cancer cells, then endogenous Par-4 will be acti-
vated, sensitizing cells to chemotherapy-induced apopto-
sis. To examine the consequences of AKT1 inhibition on
Par-4 function in human colon cancer cells, AKT1 activ-
ity was suppressed by two complimentary approaches: an
shRNA against AKT1 (pshAkt1) or phenylbutyl isosele-
nocyanate (ISC-4), a pharmacological inhibitor of AKT
[34]. Afterwards, pull-down assays and Western blot
analysis were performed on total cell lysates.Wang et al. Molecular Cancer 2010, 9:98
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Total protein levels of PKA, an activator of Par-4 [28],
NFκB p65 and NFκB p50 were unaffected by AKT1
knockdown upon transfection of pshAkt1 into native
HT29 and SW480 cells (Figure 1C). However, knockdown
of AKT1 in both cell lines promoted the interaction of
Par-4 with the p65 and p50 subunits of NFκB (Figure 1C).
Next, native HT29 and SW480 cells were treated with
increasing concentrations of ISC-4 and a viability assay
was performed. The EC50 for ISC-4-mediated apoptosis
was 43.34 μM in HT29 cells and 27.67 μM in SW480 cells
(Figure 1D). Subsequently, native HT29 cells were treated
with vehicle or two non-lethal doses of ISC-4 at 12.5 μM
and 25 μM. Par-4 was immunoprecipitated and Western
blot analysis on the immunoprecipitates was performed
with PKA, NFκB p50, and 14-3-3 antibodies. Results
showed that all treatment groups resulted in equal bind-
Figure 1 Par-4 sensitizes colon cancer cells to 5-FU-induced apoptosis and inhibits NFκB activity in an AKT1-dependent manner. (A) West-
ern analysis of Par-4 protein in HT29 cells transfected with empty vector (WT) or pCB6+-par-4. Clone 4 was used for subsequent Par-4 overexpression 
studies. (B) 5-FU treatment of Par-4- but not empty vector-transfected HT29 cells increases caspase-3 activity. Results are the mean ± S.D. of 4-5 inde-
pendent experiments. *Significantly different from vehicle (P < 0.05, Student's t-test). (C) AKT inhibition promotes Par-4 binding to NFκB. Native HT29 
and SW480 cells were treated with an anti-AKT1 shRNA, and lysates without (total) or with Par-4-immunoprecipitation (IP) were immunoblotted for 
p65, p50, AKT1, PKA, Par-4 and actin. Results are representative of 4-5 independent experiments. (D) Inhibition of AKT1 by ISC-4 promotes apoptosis. 
Native HT29 and SW480 cells were treated for 24 h with ISC-4 and subjected to an MTA viability assay. Decrease in OD reading corresponds to de-
creased viability. Results are the mean ± S.D. of 4-5 independent experiments. (E) Par-4 binding in native HT29 cells treated for 24 h with sub-lethal 
ISC-4 doses. Lysates without or with Par-4-immunoprecipitation were immunoblotted for p50, 14-3-3, PKA and actin. Results are representative of 4-
5 independent experiments. (F) Effects of Par-4 overexpression (Par-4 plasmid) and AKT1 inhibition (pshAkt1) on NFκB transcriptional activity in HT29 
cells. *Significantly different from empty vector-transfected cells (Vec only) by ANOVA and Tukey post-hoc test (P < 0.01). Negative (Neg) and positive 
controls (Pos) are reporter plasmids without promoter or with SV40 promoter sequences, respectively. Results are the mean ± S.D. of 4 independent 
experiments.
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ing of Par4 to PKA (Figure 1E). In contrast, the inhibitor
treatment resulted in increased Par-4 binding to NFκB
p50 (4-fold maximum) while causing decreased Par-4
binding to 14-3-3 (3-fold maximum), in a dose-depen-
dent manner. (Figure 1E).
Par-4 down-regulates NFκB transcriptional activity upon 
AKT1 inhibition
To determine the consequence of increased Par-4 binding
to NFκB following AKT1 knockdown, an NFκB reporter
assay was performed. Given the relative high endogenous
expression of both NFκB subunits p65 and p50 in native
HT29 cells (Figure 1C), this line was chosen for co-trans-
fection experiments with a plasmid containing the NFκB
promoter sequence upstream of the luciferase reporter
gene along with empty vector pCB6+ (Vec only), PAR-4
cDNA in pCB6+ (Par-4 plasmid) or an shRNA directed
against AKT1 (pshAkt1). Results show that transfection
with the Par-4 plasmid caused a 9-fold reduction in NFκB
activity relative to empty vector (Figure 1F). Decreasing
AKT1 levels with pshAkt1 likewise reduced NFκB activity
by 3-fold (Figure 1F).
Microarray analysis reveals alterations in expression of pro-
apoptotic and anti-apoptotic genes in Par-4-transfected 
cells
To gain further insight into the mechanism of Par-4-
mediated susceptibility to apoptosis, we performed
genome-wide expression analysis to investigate differ-
ences in gene expression between Par-4-overexpressing
and empty vector-transfected HT29 cells. A total of 692
Par-4-regulated genes were found to be significantly dif-
ferentially expressed (ANOVA with 10% or 1% FDR) (Fig-
ure 2A; Additional file 2). EASE analysis revealed that the
differentially expressed genes were overrepresented in
299 GO categories. Noteworthy were the categories
related to mitochondrial function (comprised of 38
genes), apoptosis (70 genes), cell cycle/proliferation (127
genes) and chromatin assembly and disassembly (28
genes). The identity of these downstream target genes
along with the direction of their regulation provide a pos-
sible mechanism(s) underscoring the apoptotic conse-
quence of Par-4 overexpression in colon cancer cells (see
Additional file 3 for representative genes and accompany-
ing biological function/role). Namely, a large number of
pro-apoptotic genes were up-regulated and anti-apop-
totic genes were down-regulated either directly or indi-
rectly by Par-4 (Figure 2A). Interestingly, the expression
of a number of genes associated with and/or regulating
the microRNA pathway (e.g. DROSHA, ITGB4, IGF1R,
MT1X,  MT1E,  BRAF) was likewise affected by Par-4
overexpression in HT29 cells (Figure 2A; see Additional
file 2 for gene symbols and their corresponding gene
names).
Validation of microarray results by qRT-PCR and 
immunoblot analysis
Quantitative RT-PCR was used to validate CDC27,
PDCD6, TUBB, MAPK1, CDK5 and IGF1R microarray
results, genes down-regulated by Par-4 overexpression.
Immunoblotting was used to validate Caspase 10 and
BTG1 in order to assess whether mRNA regulation was
associated with a corresponding change in protein levels.
Although levels of BCL2  m R N A  ( a  p r o - s u r v i v a l  g e n e )
were not significantly affected by Par-4 overexpression in
HT29 colon cancer cells, we included BCL2 in immunob-
lotting assays since Par-4 has been shown to regulate
BCL2 mRNA in prostate cancer cell lines [35]. Actin con-
trols were used for both the immunoblotting and the
qRT-PCR analyses. Our results demonstrate near 100%
agreement between microarray and qRT-PCR results
with the lone exception being PDCD6 (Figure 2B), and
immunoblotting revealed that up-regulation of Caspase
10 and BTG1 mRNAs was linked with protein up-regula-
tion (compare Figures 2A and 2C). Finally, immunoblot-
ting indicated that BCL2 protein levels were reduced by
approximately 60% despite a lack of change in mRNA lev-
els in HT29 cells overexpressing Par-4, suggesting a
genomic mechanism involving translational repression
via microRNAs (Figure 2C).
Overexpressing Par-4 decreases NFκB p65 and p50 
occupancy at the promoter regions of NFκB target genes
The vast majority of genes (687 out of 692) differentially
expressed in Par-4- versus empty vector-transfected
HT29 cells was identified by promoter analysis as puta-
tive NFκB target genes (see Figure 3A and Additional file
4). The clinical relevance of the Par-4-modulated genes
with NFκB binding sites can be illustrated by our recur-
rent co-regulated network analysis of public microarray
data derived from colon cancer patient specimens where
240 (including the microRNA pathway/regulation, pro-
apoptotic and pro-survival genes) out of 687 genes were
interconnected by 311 links (Figure 4A). Remarkably, the
genes comprising the recurrent colon cancer network
were also constituents of a recurrent network for prostate
cancer (Figure 4B) but not breast cancer (data not
shown). Co-regulated gene networks from a single study
(i.e. non-recurrent) have been used to gain transcrip-
tional organizational insight into a number of cancers,
such as lung, breast and liver tumors [36,37]. The advan-
tage to our recurrent analysis is the inclusion of multiple
independent microarray studies from different laborato-
ries to define robust gene links associated with cancers.
Next, we performed ChIP-qPCR assays in Par-4- versus
empty vector-transfected HT29 cells to validate the occu-
pancies of both p65 and p50 NFκB subunits at the pre-
dicted target binding sites. All target genes selected for
ChIP-qPCR assays were identified by microarray analysisWang et al. Molecular Cancer 2010, 9:98
http://www.molecular-cancer.com/content/9/1/98
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Figure 2 Global gene expression profiling identifies downstream targets of Par-4-overexpression in HT29 cells. (A) Differential expression of 
genes in HT29 cells transfected with the Par-4 gene versus empty vector. A total of 692 genes were significantly differentially expressed (Par-4-target 
genes). EASE analysis of Par-4-target genes revealed significant over-representation in GO categories such as apoptosis, cell cycle/proliferation, mito-
chondrial, chromatin remodeling, and microRNA regulation. Each row in the cluster image represents an individual gene and each column represents 
an independent hybridization experiment. The relative transcript abundance of each gene is color coded. A red indicates high expression, black indi-
cates intermediate expression and green indicates low expression. (B) Validation of selected genes by qRT-PCR. Genes downregulated by Par-4 were 
validated by qRT-PCR. Results are the mean ± S.D. of 3-4 independent experiments. *,** Significant difference between Par-4-overexpressing cells and 
empty vector-transfected cells (P < 0.05). (C) Validation of genes by immunoblot analysis. Caspase 10, BCL2, and BTG1 were assayed by immunoblot 
analysis. Actin served as loading control. Similar immunoblot results were obtained in 4-5 independent experiments.
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Figure 3 Overexpressing Par-4 reduces NFκB binding to Par-4 target gene promoters. (A) Transcription factor binding site analysis of Par-4-tar-
get genes for NFκB cis-acting sites. Response element sequence logos for NFκB family members p50 and p65 were generated from matrices in the 
TRANSFAC database using WebLogo (top panel) [76]. The height of each nucleotide base indicates overall conservation at that position. Representa-
tive sequence motifs identified by tffind for MAPK1, CDC27, CDK5, IGF1R, PDCD6 and TUBB genes are provided in the bottom panel. (B) ChIP-qPCR in 
HT29 cells transfected with empty vector pCB6+ or Par-4 expression vector. Chromatin DNA from p50- or p65-immunoprecipitates (ChIP), no antibody 
control (no Ab), or starting chromatin (Input) was amplified using quantitative PCR with primers for promoter regions of DROSHA, ITGB4, IGF1R, MT1X, 
MT1E, SLC2A1, MAPK1, CDK5, TUBB, or BRAF, and with primers for IL8 (positive control) and ACTB (nonspecific control). (C) and (D) PCR products were 
quantified by measuring 2(Ct Input - Ct ChIP), and the ratios of ChIP-to-input signals were used to yield relative NFκB p65 and p50 enrichment values. Av-
erages and standard deviations from 6 independent ChIP experiments are plotted. *Significantly different NFκB occupancies at target genes between 
Par-4-overexpressing cells and empty vector-transfected cells (P < 0.05). See Additional file 2 for gene symbols and their corresponding gene names.
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as down-regulated in response to Par-4 overexpression
and represented a spectrum of gene ontologies, including
apoptosis, microRNA pathway/regulation and cell cycle
(Figure 2A, Additional file 2). Moreover, the selected
genes were shown to be constituents of the colon cancer
recurrent network (Figure 4A). The gene IL8 was previ-
ously identified to be transcriptionally activated by NFκB
ta r g et i ng [38] a nd was  used as a  pos it ive  c o n t r o l.  T he
housekeeping gene ACTB, was used as a negative (non-
specific) control in the NFκB ChIP-qPCR experiments.
As expected, ChIP assays in empty-vector-transfected
HT29 cells demonstrated that both p65 and p50 were
bound to the IL8 promoter (Figure 3B, C and 3D). Fur-
thermore, the ChIP-qPCR assays revealed that both
NFκB p65 and p50 were significantly enriched at pre-
dicted binding elements on promoter regions of MAPK1,
CDK5, SLC2A1, IGF1R, TUBB, BRAF, DROSHA, ITGB4,
MT1X and MT1E, when compared with the no antibody
ChIP-qPCR control and the nonspecific occupancy at
ACTB (Figure 3B, C and 3D). In comparison to the empty
vector-transfected cells, the binding of NFκB p65 and/or
p50 at target sites was significantly decreased (P-value <
0.05) in the Par-4-transfected cells (Figure 3C, and 3D).
IL8 gene expression was not associated with Par-4 regula-
tion, and consequently there was no corresponding
change in NFκB binding between empty vector- and Par-
4-transfected cells. These results indicate that Par-4 mod-
ulates NFκB binding to downstream target genes in colon
cancer cells.
Par-4 partners with NFκB in the cytoplasm
Par-4 was shown to interact with NFκB in total cell
lysates following AKT1 knockdown (Figure 1C). In addi-
tion, overexpression of Par-4 significantly reduced NFκB
occupancy on target gene promoters (Figure 3B, C, and
3D) and decreased NFκB transcriptional activity in a
reporter assay (Figure 1F). It is notable that Par-4 overex-
pression does not enrich for Par-4 at NFκB-bound genes
as defined by Par-4 ChIP-qPCR (data not shown). Conse-
quently, we wanted to test the possibility that a direct
interaction of Par-4 with NFκB in the cytoplasm, thus
inhibiting nuclear translocation of NFκB, may be respon-
sible for the observed gene expression changes. Alterna-
tively, Par-4 may behave as a transcriptional modulator by
interacting with NFκB in the nucleoplasm. Colocalization
of Par-4 with NFκB p65 and Par-4 with IκB was tested
using confocal scanning laser immunofluorescent
microscopy and colocalization analysis in Par-4-overex-
Figure 4 Recurrent co-regulated gene networks in patient cancer samples. The set of Par-4-modulated genes with NFκB sites identified in HT29 
colon cancer cells were analyzed in patient cancer sample microarray data to define recurrent co-regulated gene networks. (A) Colon cancer recurrent 
co-regulated network of 240 genes with 311 links. (B) Prostate cancer recurrent co-regulated network of 276 genes with 367 links. A subset of Par-4-
modulated genes identified in HT29 cells can also be found in a recurrent co-regulated network in prostate cancer samples. This suggests that Par-4 
co-regulates overlapping genes with NFκB sites in both colon and prostate cancer samples. Red and green nodes indicate genes that were found to 
be up- or down-regulated by Par-4 in HT29 cells, respectively.
A. colon cancer B. prostate cancer
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Figure 5 Interaction of Par-4 with NFκB and IκB in the cytoplasm of Par-4 overexpressing cells. (A) Confocal immunofluorescence of Par-4-
transfected HT29 cells triple-stained for Par-4, NFκB p65 and DAPI. DAPI (blue, panel i), p65 (green, ii); Par-4, (red, iii); merge (iv) of Par-4 (red), p65 
(green), Par-4/p65 colocalization (white) and DAPI; Par-4/p65 colocalization (yellow, v); overlay of Par-4/p65 colocalization (white) and DAPI (vi). Mag-
nified images (dashed rectangles) inserted in bottom right of panels. (B) Confocal immunofluorescence on Par-4-transfected HT29 triple-stained for 
Par-4, IκB and DAPI (panels i-v) or triple stained for p65, IκB and DAPI (vi-x). DAPI (blue, i and vi); Par-4 (green, ii); p65 (green, iv); IκB, (red, iii and viii); 
merge (iv) of Par-4, IκB, Par-4/IκB colocalization (white) and DAPI; merge (ix) of p65, IκB, p65/IκB colocalization (white) and DAPI; Par-4/IκB colocaliza-
tion (v); p65/IκB colocalization (x). (C) Par-4 overexpression increases Par-4 associations with NFκB and IκB, and inhibits NFκB translocation. Left panel: 
Confocal immunofluorescence in empty vector- and Par-4-transfected HT29 cells stained for DAPI (blue), NFκB p65 (green), Par-4 (red) and Par-4/p65 
colocalization (yellow). The arrow indicates higher nuclear p65 signal in empty vector-transfected HT29 cells. Right panel: Co-immunoprecipitation of 
Par-4 followed by Western blot analysis of NFκB p65 and IκB in nuclear (N) and cytoplasmic (C) fractions of empty vector- and Par-4-transfected HT29 
cells. The upper panels depict co-immunoprecipitation with Par-4 antibody followed by immunoblotting with p65 and IκB antibodies. Bottom panels 
depict protein levels of Par-4, p65 and IκB before co-immunoprecipitation.
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pressing HT29 cells. Figure 5A depicts the immunofluo-
rescent signal for Par-4 (red) which was distributed in
both the cytoplasm and nuclei, while the signal for NFκB
p65 (green) was mainly distributed in cytoplasm. The
colocalized signal (yellow) for Par-4 and NFκB p65 was
found almost exclusively in the cytoplasm, with little to
no colocalization signal observed in the nucleus (Figure
5A). Similar restricted cytoplasmic colocalization was
seen for Par-4 and IκB (Figure 5B). The cytoplasmic colo-
calization of NFκB p65 and IκB served as an immunos-
taining control (Figure 5B).
To provide further confirmation of protein-protein
interactions among Par-4, NFκB and IκB, we performed
subcellular fractionation, co-immunoprecipitation and
Western blot analyses in empty vector- and Par-4-trans-
fected HT29 cells. Prior to co-immunoprecipitation
experiments with Par-4 antibody, empty vector-trans-
fected cells displayed a prominent p65 signal in the
nucleus, whereas Par-4 overexpression clearly reduced
this signal in the nucleus (Figure 5C, p65), suggesting that
Par-4 overexpression blocks nuclear translocation of
NFκB in colon cancer cells. Moreover, co-immunoprecip-
itation in subcellular fractions followed by Western blot
analysis demonstrated that Par-4 associations with p65
and IκB were significantly enriched in the cytoplasm
upon Par-4 overexpression (Figure 5C, IP Par-4 and WB
with p65 or IκB). Consistently, the cytoplasmic Par-4/p65
colocalized signal was enhanced by Par-4 overexpression
(Figure 5C, Par-4/p65 colocalize panel). Collectively, the
confocal colocalization microscopy and co-immunopre-
cipitation findings are consistent with a model of Par-4
interacting with NFκB p65 and IκB in the cytosol, and the
resulting partnerships presumably restricting NFκB
translocation and subsequent target gene regulation in
the nucleus.
Next, we tested whether AKT1  knockdown would
affect the amount or degree of Par-4 and p65 colocaliza-
tion. Confocal microscopy was performed in native HT29
cells treated with scrambled control (scrambled) or
shRNA against AKT1  (pshAkt1). In scrambled-treated
HT29 cells, there was a weak basal signal indicative of a
low amount of p65/Par-4 interaction in the cytoplasm
(Figure 6; Par4/p65 colocalize panel for scrambled). This
finding is consistent with results depicted in Figures 1C
(first row of blots for native HT29) and 5C (Par-4/p65
colocalize panel for empty vector-transfected HT29). Fol-
lowing  AKT1  knockdown, the cytoplasmic Par-4/p65
colocalized signal was significantly enhanced (Figure 6;
Par4/p65 colocalize panel for pshAkt1). Moreover, the
n u c l e a r  p 6 5  s i g n a l  t e n d e d  t o  b e  r e d u c e d  u p o n  AKT1
knockdown in native cells (Figure 6; p65 panels for
scrambled and pshAkt1), analogous to the confocal and
Western results found in Par-4-overexpressing versus
empty vector-transfected cells (Figure 5C). Taken
together, these results suggest that inhibition of AKT1
extensively augments Par-4/p65 interactions in cytosol
and consequently blocks nuclear translocation of p65.
Par-4 overexpression alters DROSHA and microRNA 
expression
The DROSHA gene was shown to be down-regulated by
microarray analysis (see Additional file 2, Figure 2A) and
NFκB occupancy on the promoter of DROSHA was sig-
nificantly decreased upon Par-4 overexpression in HT29
cells (Figure 3C and 3D). We explored the possibility that
these two connected events may contribute to the pro-
apoptotic activity of Par-4. Empty vector-expressing
Figure 6 Increased cytoplasmic Par-4/p65 interaction upon AKT1 
inhibition in colon cancer cells. Native HT29 cells were transfected 
with scrambled control shRNA (scrambled) or anti-AKT1 shRNA 
(pshAkt1) for 48 h. Cells were triple-stained for Par-4, NFκB p65 and 
DAPI for confocal immunofluorescence microscopy and colocalization 
analysis. DAPI (blue); NFκB p65 (Alexa 488, green); Par-4 (Alexa 594, 
red); merge of Par-4 and p65 for colocalization (white) and DAPI stain-
ing (blue); Par-4/p65 colocalization (yellow). Arrows indicate the nucle-
ar p65 signals in native HT29 cells.
Scrambled pshAkt1
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HT29 cells were transfected with an siRNA targeting
DROSHA and assayed for apoptosis. qRT-PCR analysis
confirmed  DROSHA  down-regulation by nearly 2-fold
(Figure 7A). Correspondingly, knockdown of DROSHA
promoted the susceptibility of cells to apoptosis by 5-FU
treatment (Figure 7B). It should be noted that these same
empty-vector-expressing cells were demonstrated earlier
to be resistant to 5-FU-mediated apoptosis in the absence
of DROSHA knockdown (Figure 1B).
The down-regulation of DROSHA suggested potential
dysregulation of microRNAs. Consequently, we investi-
gated the effects of Par-4 overexpression on global
microRNA expression profiles. MicroRNA expression
data from four independent Par-4-transfected cell lines
and four independent empty vector-transfected cell lines
were subjected to unsupervised principal components
analysis (PCA). Principal components 1, 2 and 3,
accounting for 69.9% of the variation in 180 expressed
microRNAs, showed clear separation between cell lines
with and without Par-4 overexpression (Figure 8A). A
student's t-test (double-sided) with multiple test correc-
tion of 10% FDR revealed 22 microRNAs were signifi-
cantly differentially expressed between Par-4 and empty
vector-transfected cells (Additional file 5). Among the 22
differentially expressed microRNAs, 13 microRNAs were
up-regulated (e.g. miR-34a, miR-100) and 9 microRNAs
were down-regulated (e.g. miR-221, miR-222) by Par-4.
Unsupervised hierarchical clustering based on the 22
microRNAs confirmed the segregation between empty
vector- and Par-4-transfected cells (Figure 8B). Lastly,
siRNA-mediated knockdown of DROSHA in HT29 cells
(thus bypassing Par-4 overexpression) was found to up-
regulate miR-34a levels by more than 2-fold compared to
scrambled control as defined by qRT-PCR (P  < 0.05,
unpaired t-test; n = 4 independent determinations). This
finding confirms a direct link between changes in
DROSHA expression and microRNA profiles.
Genes predicted to be targeted by deregulated microRNAs 
are associated with cell death pathways
TargetScan 4.2 was integrated into the Agilent Gene-
Spring GX program and used to predict the mRNAs tar-
geted by the 22 deregulated microRNAs in Par-4-
overexpressing cells. By applying strict criteria on the
TargetScan algorithm, 1187 mRNAs were identified as
predicted targets (Additional file 6). Subsequently, we
applied Ingenuity Pathway Analysis (IPA) to ascertain
potential gene networks, diseases, molecular functions,
and canonical pathways associated with the predicted
target mRNAs. Cancer, cell death, cell morphology, and
gene expression were identified as the top gene networks.
Among the set of 1187 target mRNAs, 283, 273, 150 and
244 target mRNAs were functionally associated with cell
death, cell growth/proliferation, cell cycle and gene
expression, respectively. IPA results also revealed target
mRNAs involved in the WNT/β-catenin (P = 2.37 × 10-6),
ERK/MAPK (P = 6.96 × 10-6) and PI3K/AKT canonical
signaling pathways (P = 8.31 × 10-6) (Additional file 7).
Eleven (miR-30d, miR-10b, miR-34a, miR-195, miR-
222, miR-221, miR-31, miR-7, miR-663, miR-193b and
miR-18a) out of 22 deregulated microRNAs accounted
for the 283 predicted target mRNAs linked to cell death
(e.g. pro- or anti-apoptotic genes) (see Additional file 8).
Among these eleven apoptosis-associated microRNAs,
eight were selected for validation by qRT-PCR assays.
The expression levels of individual microRNAs were nor-
malized with miR-103 expression, one of the most stable
"house-keeping" microRNA species in most human tis-
sues [39]. Our qRT-PCR results showed that miR-18a,
miR-193, miR-221, miR-222 and miR-7 were down-regu-
lated, whereas miR-195, miR-30d and miR-34a were up-
regulated in Par-4-transfected cells when compared with
empty vector-transfected cells (Figure 8C). The fold
change values from qRT-PCR results were in agreement
with the results derived from Agilent microRNA
microarrays (Figure 8C).
Figure 7 DROSHA down-regulation sensitizes cells to apoptosis 
induced by 5-FU. Empty vector-expressing HT29 cells were transfect-
ed with scrambled or DROSHA siRNA for 48 h. (A) Quantitative RT-PCR 
results confirm that DROSHA expression was decreased (P < 0.05). Re-
sults are the mean ± S.D. of 4-5 independent experiments. (B) Knock-
down of DROSHA increased apoptosis in response to 5-FU, as assayed 
with 7-AAD and Annexin V (P < 0.02). Results are the mean ± S.D. of 4-
5 independent experiments.
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Functional validation of predicted microRNA targets: miR-
34 inhibits BCL2 protein expression and induces apoptosis 
in Par-4-overexpressing cells
We sought to validate 6 TargetScan predictions from
above. MiR-34a and miR-195, both up-regulated by Par-4
overexpression, were predicted to target the pro-survival
genes BCL2 and SGK1, respectively (Figure 8B and 8C;
see Additional file 8). The Par-4-down-regulated microR-
NAs miR-221, miR-222 and miR-7 were predicted to tar-
get the pro-apoptotic genes BCL2L11  (Bim),  CDN1B
(p27) and VDAC1, respectively (Figure 8B and 8C; see
Additional file 8). Finally, the Par-4-down-regulated
microRNA miR-193b was predicted to target the pro-sur-
vival gene MCL1. None of the predicted targets were
Figure 8 Alterations of microRNA expression following Par-4 overexpression in HT29 cells. (A) Principal component analysis (PCA) of colon 
cancer cells based on global microRNA expression. Three-dimensional PCA demonstrated that global microRNA expression patterns segregated (with 
69.9% of the variance) in accordance with Par-4- (indicated in red) or empty vector-transfected (Vector) HT29 cells (indicated in blue). (B) Unsupervised 
hierarchical clustering of significantly up- and down-regulated microRNAs (as determined by t-test with 10% FDR) in Par-4- versus empty vector-trans-
fected cells. (C) Validation of microRNA profiles in response to Par-4 overexpression. MicroRNAs identified as altered following Par-4 overexpression 
were validated by qRT-PCR. Fold changes for miR-18a, miR-193b, mi-195, miR-221, miR-222, miR-30d, miR-30d, miR-34a and miR-7 are indicated. Re-
sults are the mean ± S.D. of 4-5 independent experiments. *,** Significantly different between Par-4- and empty vector-transfected cells (P < 0.05).
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shown by mRNA expression profiling to be differentially
regulated by Par-4 overexpression (Additional file 2). To
the best of our knowledge, the predicted target mRNAs
of miR-193b, miR-195 and miR-7 have yet to be function-
ally validated; whereas BCL2,  BCL2L11  (Bim) and
CDN1B (p 27) have been functionally validated (by West-
ern blot or qRT-PCR analysis) as target mRNAs of miR-
34a, miR-221 and miR-222 in human neuroblastoma,
prostate cancer and rat PC12 cell lines [40-42]. Our West-
ern blot analysis revealed a negative correlation between
microRNA and target gene expression (Figure 9A). For
example, the up-regulation of miR-34a and miR-195 was
as socia t ed  wi t h  a  d o wn - r e gu la t i o n  o f  BCL 2  a n d  SG K 1
protein levels, respectively; whereas the down-regulation
of miR-193b, miR-221, miR-222 and miR-7 was associ-
ated with an up-regulation of MCL1, BCL2L11 (Bim),
CDN1B (p 27) and VDAC1 protein levels, respectively
(Figure 9A). These results demonstrate perfect concor-
dance between microRNA expression changes and pro-
tein level changes corresponding to the target
predictions.
Next, the functional relevance of one validated
microRNA/target mRNA pair in the sensitization of
HT29 cells to apoptosis by 5-FU was explored in greater
detail. Evidence has implicated miR-34a as a crucial com-
ponent of the p53 tumor suppressor network with potent
anti-proliferative and pro-apoptotic activity [43-45]. In
addition, BCL2 mRNA was recently identified as a true
miR-34a target in neuroblastoma cell lines [40]. Here, we
hypothesized that up-regulation of miR-34a via DROSHA
deregulation causes repression of BCL2 protein expres-
sion, thus contributing to the initiation of apoptotic sen-
sitivity in Par-4-overexpressing cells. To more directly
assess the role of miR-34a in the regulation of BCL2
expression and induction of apoptosis, Par-4-overex-
pressing HT29 cells were transfected with a chemically
modified single-strand RNA antagomir, complementary
to miR-34a, to block miR-34a function. As shown in Fig-
ure 9B, BCL2 protein levels of Par-4-overexpressing cells
were substantially lower than empty vector-transfected
cells at time 0 h. However, subsequent transfection of
Par-4-overexpressing cells with the miR-34a antagomir
gradually increased BCL2 protein levels at 24 h and 72 h,
when compared with negative control scrambled oligo-
nucleotide transfected cells (Figure 9B, bottom panel). In
contrast, no significant changes in BCL2 protein levels
were detected at 0, 24, or 72 h in the empty vector-trans-
fected cells with or without miR-34a inhibition (Figure
9B, bottom panel). Finally, apoptotic sensitivity to 5-FU
decreased in Par-4-overexpressing cells transfected with
anti-miR-34a (Figure 9C). These results suggest that up-
regulated miR-34a is involved in both the repression of
BCL2 protein expression and increased 5-FU sensitivity
in Par-4-overexpressing cells.
Discussion
Par-4 plays an important role in activating intrinsic pro-
apoptotic signaling pathways [11]. Consequently, Par-4
has gained interest as a potential modality for molecular
therapy since it has been reputed to induce apoptosis
exclusively in cancer cells but not normal cells [10]. We
have demonstrated that PAR-4 mRNA levels are signifi-
cantly decreased nearly 3-fold in colon cancer patient
samples relative to their paired normal colon. While in
some cells the increase in Par-4 alone is sufficient to
cause cell death [19,24,25], the ectopic introduction of
Par-4 into HT29 colon cancer cells did not induce apop-
tosis but rather heightened cell sensitivity to the apop-
totic stimulus of 5-FU. Likewise, Par-4 has been shown to
sensitize neoplastic lymphocytes to apoptotic stimuli
such as TRAIL and CD95 [21,26]. Our study also has
uncovered a novel binding partnership between Par-4
and NFκB. In HT29 and SW480 cells, pharmacologic
(ISC-4) or genetic (pshAkt1) suppression of AKT1 activ-
ity resulted in increased Par-4/NFκB and decreased Par-
4/14-3-3 interactions. The latter finding is in line with
previous results demonstrating that binding of Par-4 to
14-3-3 is dependent on AKT1 activity [19]. Additional
partner proteins of Par-4 include ζPKC [30], TOP1 [46],
WT1 [47] and ZIP kinase [48]. Par-4/ζPKC interactions
in the cytoplasm of NIH3T3 fibroblasts [27,30], and Par-
4/TOP1 interactions in the nucleus of immortalized epi-
thelial cells impede NFκB transcriptional activity [46].
Our findings in colon cancer cells are consistent with an
alternative and possibly complimentary pathway for the
modulation of NFκB transcriptional activity via direct
Par-4/NFκB interactions in the cytoplasm. Support for
this alternative mechanism is based on the observations
that Par-4 overexpression increased Par-4/NFκB partner-
ships almost exclusively in the cytoplasm (confocal colo-
calization microscopy, subcellular fractionation and co-
immunoprecipitation), repressed NFκB gene transcrip-
tion (luciferase reporter assay), inhibited nuclear translo-
cation (subcellular fractionation and Western, confocal
colocalization microscopy), repressed NFκB binding to
cis-binding sites in a number of pro-survival and anti-
apoptotic genes (ChIP-qPCR), and affected the expres-
sion of genes primarily with NFκB binding sites in their
promoters (DNA microarrays, position weight matrix
similarity analysis). Hence, it appears that inhibition of
NFκB translocation by Par-4 can occur through partner-
ships with ζPKC [27] and/or the NFκB/IκB complex
(present study).
One of the more notable NFκB target genes down-reg-
ulated by Par-4 was DROSHA, which encodes a nuclear
RNase III enzyme responsible for the processing of
microRNAs [49]. Knockdown of DROSHA  by siRNA
resulted in increased apoptotic responsiveness of colon
cancer cells to 5-FU, portending a potential role of theWang et al. Molecular Cancer 2010, 9:98
http://www.molecular-cancer.com/content/9/1/98
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microRNA pathway in Par-4-mediated apoptotic sensi-
tivity. MicroRNAs are important in the regulation of cru-
cial biological processes and alterations in microRNA
expression are proposed to play a role in the pathophysi-
ology of many, perhaps, all human cancers [50,51]. Our
findings suggest that DROSHA  down-regulation, in
response to Par-4 overexpression, disturbs global
microRNA biogenesis, and that deregulation of
microRNA expression will have consequential wide-
spread effects on the post-transcriptional regulation of
genes (mRNAs targeted by microRNAs). It is unclear at
this time why Par-4-mediated down-regulation of
DROSHA in HT29 cells would be associated with both a
down- and up-regulation of microRNAs. Notwithstand-
ing, overexpression or recruitment of DROSHA has been
shown both to down- and up-regulate microRNAs in car-
cinoma samples [52,53]. These results suggest that a com-
plex regulatory circuit exists between NFκB activity and
Figure 9 Par-4 overexpression modulates translation of apoptosis-associated genes and sensitizes HT29 cells to 5-FU-mediated apoptosis 
via miR-34a regulation of BCL2 expression. (A) Post-translational regulation of apoptosis and anti-apoptosis gene expression by microRNAs upon 
Par-4 overexpression. Western analysis was performed to assess levels of anti-apoptotic proteins (BCL2, MCL1 and SGK1) and apoptotic proteins (Bim, 
p27 and VDAC1) targeted by the corresponding differentially expressed microRNAs in empty vector- and Par-4-transfected cells. Note that both miR-
221 and miR-222 are predicted to target BCL2L11 (encoding Bim) and CDKN1B (p27). Heat map represents the relative microRNA expression levels be-
tween empty vector- and Par-4-transfected cells. (B) Western of BCL2 in empty vector- and Par-4-transfected cells treated with or without miR-34a 
antagomir. Par-4-overexpressing and empty vector-expressing cells were transfected with scrambled or miR-34a antagomir. Transfected cells were 
harvested at 0, 24, and 72 h to assess the effect of inhibiting miR-34a on BCL2 protein levels. Quantification of relative BCL2 protein levels were calcu-
lated from BCL2-to-actin ratios. Results are the mean ± S.D. of 3-4 independent experiments. *Significantly different from 0 h following miR-34a an-
tagomir treatment (P < 0.05). (C) Inhibition of miR-34a in Par-4-overexpressing HT29 cells reverses apoptotic sensitization to 5-FU treatment. Empty 
vector-expressing cells transfected with scrambled antagomir (Vector with Scrambled), Par-4-overexpressing cells transfected with scrambled antag-
omir (Par-4 with Scrambled) and Par-4-overexpressing cells transfected with miR34a antagomir (Par-4 with anti-miR-34a) for 24 h were treated with 
100 μM 5-FU for an additional 24 h and assayed for apoptosis. Results are the mean ± S.D. of 4-5 independent experiments. #Significantly different 
from Par-4 with Scrambled (P < 0.05).
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DROSHA  regulation of microRNA biogenesis in colon
cancer cells.
The functional consequences of DROSHA down-regu-
lation and associated microRNA deregulation in Par-4-
overexpressing HT29 cells was assessed computationally.
Sixty percent of the predicted target mRNAs of the
deregulated microRNAs appear to be associated with
apoptosis, cell proliferation and cell cycle regulation. We
have successfully validated a subset of these predictions
by Western blot analysis. Moreover, one particular dereg-
ulated microRNA miR-34a, which was up-regulated in
response to overexpressed Par-4, was functionally char-
acterized in greater detail. Inhibition of miR-34a in Par-4-
overexpressing cells resulted in an up-regulation of BCL2
protein with a corresponding decrease in apoptotic sensi-
tivity to 5-FU. It should be noted that a primary tran-
script containing miR-34a can be directly transactivated
by p53 [43,45]. Our findings support an alternate indirect
pathway, involving Par-4/NFκB/DROSHA, that promotes
apoptosis. Interestingly, Cheema et al. reported on a
pathway that directly regulates BCL expression via Par-4
interactions with transcription factor WT1 at the BCL2
gene promoter in prostate cancer cell lines [35]. We did
not observe changes in BCL2 mRNA levels in Par-4-over-
expressing HT29 cells, suggesting that the primary mech-
anism of down-regulating BCL2 protein was post-
transcriptional.
A number of Par-4/NFκB/DROSHA-regulated microR-
N As  i d e n t i fi ed  i n  t h is  s t u d y  h a v e  bee n  r epo rt ed  t o  be
associated with tumorigenesis in patients. For example,
miR-221, and miR-222 are up-regulated, while miR-34a,
miR-18a, miR-30d and miR-34b are down-regulated in
colon cancer [54-56]. Moreover, miR-221, miR-222 and
miR-134 are up-regulated in lymphocytic leukemia, pan-
creatic, liver, esophagus, or thyroid cancers [57-59],
whereas miR-34a and miR-100 are down-regulated in
neuroblastoma [60], esophagus and ovary cancers [8,58].
Of interest, the direction of regulation for many microR-
NAs, including miR-34a, in patient tumors is consistent
with our in vitro cell line model.
Conclusions
In conclusion, Par-4 may play a significant role in the
treatment of colon cancer by increasing the sensitivity of
colon cancer cells to undergo apoptosis through the bind-
ing of Par-4 to NFκB in the cytoplasm, thus inhibiting
translocation of NFκB to the nucleus and altering both
DROSHA  and microRNA expression. Accordingly,
enhancing Par-4 activity and/or modifying the expression
of microRNA processing genes or microRNAs them-
selves may provide an effective strategy for the treatment
of colon cancer.
Methods
Cell culture
Human colon cancer cells, SW480 and HT29 (American
Type Culture Collection, Manassas, VA), were cultured in
RPMI (Cellgro, Mediatech, Inc, Manassas, VA) contain-
ing 10% FBS and Pen/Strep at 37°C and 5% CO2. Both
SW480 and HT29 cells are part of the NCI-60 panel of
cancer cell lines and represent two colon cancer lines
with a wealth of biochemical, molecular, proteomic and
genomics data, providing an opportunity for meta-analy-
sis [61-63]. Cells were transfected with either rat par-4
cDNA in pCB6+ or with empty vector using Fugene 6
reagent (Roche Diagnostics, Indianapolis, IN, USA).
Transfectants were selected with G418 (Gibco, Carlsbad,
CA) and colonies expanded and assayed for Par-4 expres-
sion. HT29 cells were transfected with 1 μg/ml DROSHA
siRNA or the corresponding scrambled siRNA (Thermo
Scientific Dharmacon, Lafayette, CO) using Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA).
Subcellular fractionation, immunoprecipitation and 
Western blotting
Antibodies used were Par-4, NFκB p 50, p 65, BCL2,
MCL1, BCL2L11 rabbit polyclonal, SGK1, VDAC1 goat
polyclonal, CDN1B (p27) mouse monoclonal (Santa
Cruz, Santa Cruz, CA, USA), AKT1 mouse monoclonal
(Cell Signaling, Danvers, MA, USA), PKA goat poly-
clonal, PARP rabbit polyclonal (Upstate Cell Signaling
Solutions, Charlottesville, VA, USA), and β-actin mouse
monoclonal (Sigma, Saint Louis, MO, USA). Subcellular
fractionations were performed using the NE-PER Nuclear
and Cytoplasmic extraction reagent kit (Pierce Biotech-
nology, Rockford, IL, USA) according to the manufac-
turer's instructions. Western blotting and
immunoprecipitation assays were performed as previ-
ously documented [64]
Synthesis of ISC-4
ISC-4 was synthesized following a method recently devel-
oped by Sharma et al. [65] Briefly, a solution of triphos-
gene (1.48 g, 5.0 mmol) in CH2Cl2 (15 mL) was added
dropwise, for a period of 1 h, to a refluxing mixture of
phenylbutyl formamide (1.77 g, 10.0 mmol), triethylam-
ine (4.35 g, 6.0 mL, 43.0 mmol) and 4Å molecular sieves
in CH2Cl2 (50 mL). The mixture was refluxed for an addi-
tional 2.5 h. Selenium powder (1.58 g, 20 mmol) was
added and the resulting mixture was refluxed for addi-
tional 7 h. The mixture was purified by silica gel column
chromatography (EtOAc/hexanes 5:95) to yield 1.7 g
(71%) of ISC-4 as viscous oil.Wang et al. Molecular Cancer 2010, 9:98
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Assays of apoptosis
For caspase-3 activity assay, cells were cultured in 6-well
plates with half of the wells treated with 100 μM 5-FU.
After 24 hrs cells were harvested and assayed for apopto-
sis using the Caspase-3 Assay kit from BD Biosciences
Pharmingen (San Diego, CA). For annexinV/7AAD assay,
cells were cultured in a 12 well plate and treated as above.
Cells were trypsinized, washed, and stained with Annexin
V, conjugated with PE, and 7AAD (BD Biosciences, San
Jose, CA). Staining was detected by flow cytometry. MTS
assay was performed in 96 well plates according to manu-
facturer's protocol (Promega Corp, Madison, WI). After
addition of MTS solution, plates were incubated at 37° for
4 h and read at 490 nm using a plate reader.
Treatment with AKT inhibitors
HT29 cells were treated with 3 to 50 μM ISC-4 for 48
hours. In vitro cytotoxic efficacy was measured using 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) viability assay
(Promega, Madison, WI, USA).
NFκB reporter activity assay
NFκB activity was assessed using the Cignal™ NFκB
Reporter Assay Kit (SuperArray, Bioscience Corporation,
Frederick, MD, USA). Cells were transfected with 6.6 μg/
ml of the reporter plasmids. Cells were incubated 48
hours, and assayed using the Dual-Luciferase Reporter
Assay System (Promega Corporation, Madison, WI,
USA). Cells were lysed, proteins quantitated, and 26 μg
protein added to each well of a 96-well opaque white
plate. The plate was read in a Synergy plate reader, with
K C 4  s o f t w a r e  ( B i o - T e k  I n s t r u m e n t s ,  W i n o o s k i ,  V T ,
USA). Firefly luciferase substrate was injected to assess
luciferase activity under the control of the NFκB pro-
moter. Renilla luciferase substrate was added to assess
transfection efficiency. Each well was read 11 times after
a 2 second delay over a period of 10 seconds.
Gene expression profiling analysis
Gene (mRNA) expression profiling experiments were
performed on a 39,936 human cDNA microarray employ-
ing a common reference design as previously described
[66,67]. LOWESS data normalization, experimental noise
determination, and statistical analysis with false discov-
ery rate (FDR) to correct for multiple testing were per-
formed as described previously [66-68]. Biological
themes associated with the differentially expressed genes
were identified using gene ontology (GO) categories in
the Expression Analysis Systematic Explorer (EASE)
application [69], which is executable using TIGR Multi
Experiment Viewer (TMEV; available at http://
www.tigr.org/softlab). A Fisher's Exact score p < 0.05 was
considered significant.
Real-time RT-PCR validation of mRNA expression
Quantitative RT-PCR assay was performed on the ABI
7900 HT Sequence Detection System using Assay on
Demand primers and probes and TaqMan Universal PCR
Master Mix (Applied Biosystems, Foster City, CA). PCR
conditions were 2 minutes at 50°C, 10 minutes at 95°C
and 40 cycles of 15 seconds at 95°C and 1 minute at 60°C.
ABI SDS 2.2.2 software and the 2-ΔΔCt analysis method
[70] were used to quantitate relative amounts of product
using beta-actin as an endogenous control.
Promoter analysis for NFκB binding sites
For each differentially regulated gene identified by
microarray analysis, 5,000 bases of the proximal pro-
moter region (-5,000 to -1) were extracted from
ENSEMBL database http://www.ensembl.org. Position
weight matrix (PWM) models representing the binding
sites for NF-κB family members p50 and p65 were taken
from version 7.0 of the TRANSFAC database [71], using
matrix IDs 'V$NFKAPPAB50_01' and
'V$NFKAPPAB65_01', respectively. Matches to each
PWM were identified in promoter regions using a slightly
modified version of tffind [72], with default matrix simi-
larity thresholds.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitation (ChIP) reagents were
purchased from Upstate Cell Signaling (Billerica, MA,
USA). HT29 colon cancer cells (1 × 106) were transfected
with empty vector or Par-4 expressing vector and treated
with 1% formaldehyde for 15 min at 37°C to crosslink
protein-chromatin complexes. The fixed cells were
washed twice with cold PBS, and chromatin DNA was
harvested and sonicated for ChIP assays. The ChIP assays
were performed according to the manufacturer's proto-
col. Anti-NFκB p50 and p65 antibodies used for ChIP
assays were from Abcam (Cambridge, MA, USA) and
Santa Cruz (Santa Cruz, CA, USA), respectively. In ChIP
experiments, quantitative real-time PCR (qPCR) analysis
with SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) were calculated by measuring the
ratios of ChIP-to-Input, and the non-antibody-treated
chromatin immunoprecipitated samples were used as a
negative control. NFκB occupancy at IL8 and ACTB pro-
moters served as additional positive and negative con-
trols, respectively, for the ChIP-qPCR experiments. All
primers used for quantitative PCR are listed in Supple-
mental data (Additional file 9).
Immunocytochemistry with confocal fluorescence 
detection
Empty vector-transfected HT29 cells, Par-4-overexpress-
ing HT29 cells, and native HT29 cells transfected withWang et al. Molecular Cancer 2010, 9:98
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scrambled or pshAkt1 were grown in 6-well plates on
glass coverslips. After culturing for 24 h (empty vector-
and Par-4-transfected cells) or 48 h (scrambled- and
pshAkt1-transfected cells), cells were fixed with 3.7%
formaldehyde in phosphate-buffered saline (1×PBS) for
15 min at room temperature and washed once with
1×PBST (1×PBS with 0.1% Tween-20). Cells were perme-
abilized with 0.1% Triton X-100 in 1×PBS for 5 min fol-
lowed by two washes with 1×PBST. The cells were then
treated with blocking buffer (5% FBS in 1×PBS) for 1 h,
and incubated with the rabbit polyclonal anti-NF-κB p65,
Par-4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
or p105/p50 (Abcam, Cambridge, MA, USA) antibody, or
the mouse monoclonal anti-Par-4 or IκB-antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) at 1:400 dilu-
tion for overnight at 4°C, followed by two washes with
1×PBST. For the secondary antibodies, Alexa Fluor 488
donkey anti-rabbit IgG and Alexa Fluor 594 goat anti-
mouse IgG (Molecular Probe, Carlsbad, CA, USA) were
used at 1:1000 dilutions and incubated for 1 h at room
temperature in the dark, and then washed three times
with 1×PBST. Coverslips were mounted onto glass slides
with Prolong Gold antifade reagent with DAPI (Molecu-
lar Probe, Carlsbad, CA, USA) to detect the cell nuclei.
Confocal microscopy was performed with a Zeiss Axio-
plan fluorescence microscope coupled with a Zeiss
LSM710 Laser Scanning System (Zeiss, Berlin, Ger-
many). Colocalization analysis was performed using
Volocity 5.0 software (PerkinElmer, Waltham, MA, USA).
Positive PDM (product of the difference from the mean)
channels were generated to visualize the highly-corre-
lated colocalization of two fluorescence-labeled proteins
(Figure 5A-v, B-v and 5B-x). Images were processed with
Volocity software (PerkinElmer, Waltham, MA, USA).
Recurrent co-regulated gene network analysis
Recurrent co-regulated (ReCo) gene networks were con-
structed from 334 colon cancer gene expression microar-
ray studies downloaded from the Expression Project for
Oncology repository https://expo.intgen.org/geo/listPub-
licGeoTransactions.do and Gene Expression Omnibus
(GEO) [73]. In a separate analysis, we also inspected the
ReCo links in prostate-disease networks given that Par-4
is known to have an important role in prostate cancer .
Using only data corresponding to a specific tissue and
disease state (i.e. colon cancer or prostate cancer), a co-
regulated network was constructed by linking gene pairs
that were significantly coexpressed across the corre-
sponding samples. Network analysis was restricted to the
set of genes initially identified as Par-4-targets containing
NFκB binding sites in colon cancer cell lines. A Pearson
correlation r was calculated for all pairs of genes (i, j):
where N is the number of samples, Eis is the expression
level of gene i in sample s, μi is the mean expression level
of gene i across all samples, and σi is the standard devia-
tion of the expression level of gene i.
Pearson correlations were then transformed to Z-
scores using the Fisher Z transformation:
Intuitively, the Fisher Z transformation assigns higher
significance to genes with strong correlations across a
greater number of samples. Zij's can be interpreted as Z-
scores which provides an estimate of the significance of
two gene's correlation across the set of conditions. While
the Z-score would be exact if the expression levels across
the conditions were independent and normally distrib-
uted, which is clearly not true in our case, it still provides
a good measure of relative correlation for a single experi-
ment useful for ranking gene pairs against one another.
We calculated a tissue-disease-specific ReCo network
by combining the Z scores of gene pairs across individual
studies of the same tissue-disease state. We first con-
verted the Z-scores for each gene pair (i, j) in each study S
to P values using the following rank ratio transformation:
where L is the total number of gene pairs in the dataset.
Then, the P values were combined across studies using
the Mudhalker-George's t-statistic to derive a recurrent
co-regulated (RECO) score:
where Ns is the total number of studies. The resulting
RECO score gives a single value quantifying the strength
of coexpression of each gene pair (i, j) across all available
studies of the same tissue-disease state.
microRNA microarray hybridization and data analysis
Total RNA from HT29 cells was harvested in QIAzol
Lysis reagent (Qiagen, Valencia, CA, USA), and
microRNA isolated using miRNeasy Mini Kit (Qiagen,
Valencia, CA, USA) according to the manufacturers'
instructions. RNA quality was assessed and quantified
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using the RNA 6000 Nano Kit (Agilent Technologies,
Inc., Santa Clara, CA). microRNeasy-isolated RNA (250
ng) was used as input in the labeling reaction, and the
entire reaction was hybridized onto an Agilent human
genome microRNA microarray V1 (Agilent Technolo-
gies, Inc., Santa Clara, CA) containing 20-40 probes for
each of 470 microRNAs for 20 hours at 55°C. Hybridiza-
tion signal intensities were extracted using the Agilent
Feature Extraction software. Raw mean signal, total probe
intensities and total gene intensities were uploaded into
GeneSpring GX 10.0 software (Agilent Technologies,
Santa Clara, CA). Poor spots, as reported in the raw data
file, were flagged as A (absent). The background-sub-
tracted signal intensities were log2 transformed and quan-
tile normalized. GeneSpring GX 10.0 and Partek
Genomic Suite 6.2 (St. Louis, MO) were used for princi-
pal component analysis (PCA), statistical analysis, and
hierarchical clustering. Differential expression was
assessed using a two sample t-test (double-sided). Cor-
rected P-values were adjusted for multiple testing using
Benjamini and Hochberg's FDR at 10% [74].
Real-time RT-PCR validation of microRNA expression
qRT-PCR was performed using the NCode™ EXPRESS
SYBR® GreenER™ microRNA qRT-PCR Kit (Invitrogen,
Carlsbad, CA). Poly(A) tailing and RT reactions consisted
of 4 μl 5× reaction mix, 2 μl 10× SuperScript enzyme mix,
0.5 mL and 200 ng total RNA in a final volume of 20 μl.
Following poly(A) tailing and RT steps, 0.17 μl of the RT
product was transferred into a PCR reaction mixture
consisting of 10 μl Express SYBR green qPCR SuperMix,
0.4 μl microRNA-specific forward primer (10 μM), 0.4 μl
universal qPCR primer (10 μM) in a final volume of 20 μl.
PCR cycling began with template denaturation and hot
start Taq activation at 95°C for 2 min, then 40 cycles of
95°C for 15 sec, and 60°C for 1 min performed in a 7300
Real-Time PCR System (Applied Biosystems, Foster City,
CA). MiR-103 was used as the internal standard reference
in the qRT-PCR reaction [39]. Normalized expression
was calculated using the comparative Ct method and fold
change was derived from the equation 2-ΔΔCt for each
microRNA.
Identification of microRNA target genes and pathway 
analyses
Target Scan database (version 4.2, http://www.tar-
getscan.org) was integrated to GeneSpring GX and used
for the identification of target genes. Target Scan allows
identification of target mRNAs for any specific
microRNA, based on the context score percentile [75].
Differentially expressed microRNAs with 10% FDR were
imported into the TargetScan algorithm and the target
mRNAs with high context scores (context percentile of
80) were retained for further analysis. Predicted target
mRNAs were imported to GeneSpring GX 10.0 and Inge-
nuity Pathway Analysis programs to identify significant
biological pathways, associated network functions, and
associated molecular and cellular functions.
Inhibition of miR-34a expression
Cells grown to 60-70% confluence in 6-well plates were
transfected with 150 pmole anti-miR-34a inhibitor or
negative-control oligonucleotide (Ambion, Austin, TX)
using Lipofectamine 2000 according to manufacturer's
protocol. The medium was replaced with fresh medium
after 24 hours, and cells were allowed to grow for another
48 hours prior to functional analysis.
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tumor necrosis factor-related apoptosis-inducing ligand;
TNFα: tumor necrosis factor alpha.
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